enVVeno Medical Corp. (NVNO) 宣布获得美国食品药品监督管理局(FDA)的研究设备豁免(IDE)批准,将启动该国首项针对非手术置换静脉瓣的关键性临床研究。这一里程碑式的监管许可标志着该公司在静脉疾病治疗领域取得重大突破。
enVVeno Medical Corp. (NVNO) 宣布获得美国食品药品监督管理局(FDA)的研究设备豁免(IDE)批准,将启动该国首项针对非手术置换静脉瓣的关键性临床研究。这一里程碑式的监管许可标志着该公司在静脉疾病治疗领域取得重大突破。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.